Philips Extends Leadership In Patient Monitoring By Buying BioTelemetry For $2.8Bn
Executive Summary
Philips is already the leader in hospital patient monitoring and adding BioTelemetry will make it also the top provider of ambulatory cardiac diagnostics and monitoring systems.
You may also be interested in...
News We’re Watching: New FDA Guidance on DHTs and COVID-19 Antibodies, Device Shortage List Updated, Philips False Claims Case Settled
This week, the US FDA released guidance documents on COVID-19 monoclonal antibodies and the use of digital health technologies in remote trials; Philips’ Biotelemetry pays $14.7m to settle False Claims Act allegations; recalls of bronchoscopes, tracheostomy trays and software; and more.
CEO: Triple Headwind Cannot Blow Philips Off Strategic Course
Frans van Houten has promised a summer update on Royal Philips’ medium-term outlook after the company was hit from all sides in late 2021. He expects the resulting headwinds to persist into early 2022.
Philips Strikes Record High Number Of Long Term Health Care Partnership Deals
Royal Philips closed out the first year of COVID-19 with 7% revenue growth in the fourth quarter. CEO Frans van Houten says low single digit growth is the target for fiscal 2021.